Skills Required by Pharmacologists and Physiologists in Today s Pharmaceu:cal Industry

Similar documents
How Targets Are Chosen. Chris Wayman 12 th April 2012

Introduction to Drug Design and Discovery

Engage with us on Twitter: #Molecule2Miracle

From Discovery to Development of new Drugs. and pitfalls along the way. by Kim Dekermendjian, PhD in Medicine BD & Key Account manager

NIH-RAID: A ROADMAP Program

Toxicology - Problem Drill 24: Toxicology Studies in Pharmaceutical Development

Career Growth Areas in Physiology / Pharmacology

The Impact of Genomics on Drug Development, Clinical Research, and Medical Practice

From Bench to Bedside. Russ H. Read June 23, 2014

Centre for Drug Design and Discovery CD3. Centre for Drug Design and Discovery

= -1-EUROPEAN CD3. "Stimulating innovation in drug discovery" 21 May 2010 Innovation in Healthcare. Centre for Drug Design and Discovery

Antibody Discovery at Evotec

Introduction of Development Center for Biotechnology TAIWAN

INTRODUCTION TO DRUG DISCOVERY

Programa Cooperación Farma-Biotech Neurociencias G79

Drug Repositioning. Cresset European User Group Meeting 21 st June 2012

TARGET VALIDATION. Maaike Everts, PhD (with slides from Dr. Suto)

Drug Development: Why Does it Cost so Much? Lewis J. Smith, MD Professor of Medicine Director, Center for Clinical Research Associate VP for Research

Chemoinformatic Tools for the Hit Discovery Process

Integration of FDSS7000 into a modular robotic system for Open Innovation drug discovery

DRUG DISCOVERY AND DEVELOPMENT-PRECLINICAL ASPECTS

Real World Drug Discovery A Chemist's Guide to Biotech and Pharmaceutical Research

Drug Discovery Toxicology Webinar

Maximizing opportunities towards achieving clinical success D R U G D I S C O V E R Y. Report Price Publication date

Biotech Showcase 2016

Drug Discovery and Development at NIH for Rare and Neglected Diseases September 29, 2009

Bayer Pharma s High Tech Platform integrates technology experts worldwide establishing one of the leading drug discovery research platforms

Innovative Pharmaceutical Solutions for Discovery Chemistry, Biology and cgmp Manufacturing

Using Computational Chemistry to Identify New Uses for Old Medicines

Supplementing the Immune System with Plant-Produced Antibodies

IMPROVE SPEED AND ACCURACY OF MONOCLONAL ANTIBODY BIOANALYSIS USING NANOTECHNOLOGY AND LCMS

Unlocking protein production with translational read-through for rare genetic diseases. Investor Presentation February 2018

University of California Center for Accelerated Innovation

First Quarter 2018 Financial Results. May 8, 2018

Duncan Holmes European Head Discovery Partnerships with Academia GlaxoSmithKline

Presidential Commission for the Study of Bioethical Issues 2 nd meeting September

Fast Track Drug Development The Clinical (Caleidoscopic) Perspective

Momenta Pharmaceuticals, Inc. 36 th Annual J.P. Morgan Healthcare Conference

Development of a new medicinal product. as. MUDr. Martin Votava, PhD.

Introduction to Drug Development in Commercializing Biomedical Technology

REIMAGINING DRUG DEVELOPMENT:

leading the way in research & development

Agreed with W. Cornell Graduate Program and Tri-I

The Need for Scientific. Data Annotation. Alick K Law, Ph.D., M.B.A. Marketing Manager IBM Life Sciences.

CONFLUENCE LIFE SCIENCES ACQUISITION

Datamonitor Healthcare Pharma intelligence informa Datamonitor Healthcare Content Calendar

NIAID Resources to Facilitate Medical Countermeasure Development

Technology Development Funding Program Round 3

The Right Molecules. Designed. Delivered.

What IMI means for POLAND

IGPNS Recommended Electives List

Stem Cells, Regenerative Medicine and cgmp (GTP)

LA RICERCA TELETHON PER LE MALATTIE RARE TELETHON RESEARCH ON RARE DISEASES

Pharmacy Benefit Drug Trends and Pipeline. Casey Robinson, PharmD, MBA, Cigna Pharmacy Management

Pharmacy Benefit Drug Trends and Pipeline Casey Robinson, PharmD, MBA, Cigna Pharmacy Management

INTRODUCTORY GUIDE TO CNS DRUG DISCOVERY

Linker p. 177 Helper Lipid p. 178 Delivery to Target Cells p. 180 Cell Entry p. 182 Receptor-Mediated Uptake p. 182 Endosomai Release p.

Successful Academia-Pharma Collaboration Drug Discovery and Clinical Development

Resources for the Microbiology and Infectious Diseases Research Community

SMEs in IMI2 Calls for Proposals

NEXT BIG WAVE IN PHARMACEUTICAL INDUSTRY

Medical Topics: Gene Therapy. E. Anne Jackson, FSA MAAA July 30, 2018

Anti-cancer drug discovery: from bench to bedside

CHAPTER 4. Milestones of the drug discovery

Discovery of a First-In-Class Topically Bioavailable Kit Inhibitor With Clinical Activity Using Computational Chemogenomics Technology

Advanced Therapeutic Antibody Discovery with Multiplexed Screening

Astellas to Acquire Agensys, Inc.

A unique Collaborative Model for the Discovery of New Therapeutic Approaches

Biomarkers in Clinical Development: Implications for Personalized Medicine and Streamlining R&D in the UK and EU region

Course Agenda. Day One

Global Development Challenges: Classical and Advanced Therapy Medicinal products

Envigo Corporate & Industry Overview. Rutgers University

The science behind Betalutin : why is it unique? Roy H. Larsen PhD Sciencons AS, Oslo, Norway

Marina Biotech Monetizes UNA Intellectual Property Estate through Agreement with Arcturus Therapeutics

Published on Horizon 2020 ( Tuesday, 13 January, Ebola virus. Latest on Silver (September, 2015)

Biomolecular Characterization for Rational Drug Design. Maria João Romão

Alexandra Richardson, PhD, CLP April 2015

Affinity Reagents: The Landscape and Affimer Technology Competitive Advantages

Development Stage of Therapeutic Vaccines: The Regulator s View

Delivering on the Promise of RNA- Based Therapeu;cs

OSNIG Discussion: Commercialization Issues: regulatory and workflow. Michael F Tweedle, PhD

From Molecules To Medicine

Trubion Investor Presentation BioCentury NewsMakers in the Biotech Industry Conference September 6, 2007

Pharmacology. Chatchai Chinpaisal, Ph.D. Department of Pharmacology and Toxicology, Faculty of Pharmacy, Silpakorn University.

Technology Transfer, Academic and Industry Cooperations

Accelerating Therapeutic Development through a look at current Regulatory Applications A Non-Clinical Perspective

Regulatory Framework for Gene Therapies Incorpora:ng Human Genome Edi:ng

Jefferies Global Health Care Conference. June 1, 2015

Innovative Medicines Initiative - the story so far

Marineinspired Oncology

Week 1: Discovery Biology Basic knowledge and tools used in Research and Development

Regeneron Reports Third Quarter 2010 Financial Results and Business Highlights

GSK R&D. Dr Ashley Bates Discovery Research GlaxoSmithKline Australia. Greenford (UK) Harlow (UK) Stevenage (UK) Verona (ITA) RTP (USA) Tokyo (JPN)

The Pharmaceu+cal Technology Specialists.

Immunodiscovery developing antibodies for research, diagnosis and therapy MATS OHLIN

The National Institutes of Health ICs: mission and funding strategies

NIH Blueprint for Neurotherapeutics: A novel approach to early stage drug discovery research funding

PharmaMar A Biopharmaceutical Company

MRC Technology. A Life Science Specialist Technology Transfer Company. Skaggs School of Pharmacy and Pharmaceutical Sciences, December 2011

MODEL-BASED DRUG DEVELOPMENT: A FDA CRITICAL PATH OPPORTUNITY

Transcription:

Skills Required by Pharmacologists and Physiologists in Today s Pharmaceu:cal Industry Iok- Hou Pang, PhD Pharmaceutical Sciences!! University of North Texas Health Science Center!

Outline of Presenta:on Skills Related to Today s Trends in Therapeu<c Approaches (Non- tradi<onal Pharmaceu<cal Agents) Drug Discovery Process in Pharma Comparison between academic & industrial research Differences between large & small pharma 2

Trends in Therapeu:c Approaches (Non- tradi:onal Pharmaceu:cal Agents) Biological An<body An<body- drug conjugate Fusion protein Gene Therapy RNA Interference 3

An:body Since mid 1980s, dozens were approved for human use In 2013 One approved Itolizumab (psoriasis) Three NDA submived Vedolizumab, Ramucirumab, Obinutuzumab Many in Phase III Trials Cancer, rheumatoid arthri<s, psoriasis, asthma, Alzheimer s disease, SLE, mul<ple sclerosis 4

An:body- Drug Conjugate Brentuximab vedo<n (Adcetris) Hodgkin lymphoma Anaplas<c large cell lymphoma Trastuzumab emtansine Approved 2013 Breast cancer 5

Fusion Protein Aflibercept (Eylea ; VEGF Trap) Fusion protein of key domains from human VEGF receptors 1 (VEGFR1) and 2 (VEGFR2) with human IgG- Fc Binds to VEGF- A & PLGF Approved for Wet AMD Macula edema due to CRVO 6

Gene Therapy Correct gene<c disorders 1800+ gene<c disorders in humans; only a small frac<on can be treated by tradi<onal means CFTR in Cys<c fibrosis RPE65 in Leber congenital amaurosis β- Thalassemia Hemophilia Deliver therapeu<c proteins TNFα Fc for rheumatoid arthri<s Oncoy<c viruses Glioblastoma 7

RNA Interference SiRNA Cancer AIDS- related non- Hodgkin s lymphoma Liver cancer Various solid tumors Re<nal Diseases Diabe<c macular edema Age- related macular degenera<on Asthma Respiratory syncy<al virus infec<on Familial Adenomatous Polyposis 8

Trends in Therapeu:c Approaches (Non- tradi:onal Pharmaceu:cal Agents) Biological Gene Therapy RNA Interference Different from tradi<onal small molecule drugs Chemical physical proper<es Pharmacokine<cs Molecular kine<cs Drug discovery process Regulatory requirements 9

Drug Discovery Process in Pharma Comparison: Academic vs Industrial Research Drug Discovery Process Differences between Large & Small Pharma Skills for Pharmaceu<cal Industries Research Beyond Research 10

Comparison Academic vs Industrial Research Academic Generate & distribute knowledge Publica<on & patent Teach Projects likely more opportunis<c More individualized approach Project leader = Captain of a ship More ownership & control of project Industrial Generate product & profit Patent, trade secret, publica<on Convince peer & management Projects are highly goal- oriented Always team approach Project leader = Captain of a team Reassignment not uncommon 11

Typical Drug Discovery Process Management Approval Target Iden:fica:on Hit to Lead Lead Op:miza:on Proof of Concept Clinical Research 12

Target Iden:fica:on - Omics Bioinforma<cs Biochemistry, Physiology Disease Mechanism Iden<fica<on of Possible Targets Confirma<on/Valida<on of Target Team Members: Academic Collaborator Biochemist Cell Biologist Pharmacologist Physiologist Chemist Development of Screening Assay(s) Discovery of Lead Class Drug Discovery Target 13

Hit to Lead Compound Procurement Compound library Synthesis Licensing In Vitro Efficacy Assay Biochemistry Cell or Tissue Molecular Modeling & Design Team Members: Med Chemist Organic Chemist Biochemist Cell Biologist Pharmacologist Physiologist Pharmaceu<cs Licensing In Vivo Efficacy Assay Lead Iden<fica<on 14

Lead Op:miza:on Genotox herg Acute Tox Lead Large- Scale Synthesis Formula<on Clinical Candidate Lead Backup Detailed Mechanism Studies In Vivo Efficacy Stability Team Members: Project Manager Org Chemist Med Chemist Physiologist Pharmacologist Pharmaceu<cs Toxicologist 15

Clinical Candidate Proof of Concept Scale- up & GMP Synthesis Analy<cal Chemistry Formula<on Stability ADME Chronic Tox IND Prepara<on Metabolite Characteriza<on Team Members: Project Manager Clinical Researcher Regulatory Affairs Analy<cal Chemist Chemist Pharmacologist Pharmaceu<cs ADME Expert Toxicologist Clinical Study Design, Planning, Execu<on 16

Typical Drug Discovery Process Management Approval Target Iden:fica:on Hit to Lead Lead Op:miza:on Proof of Concept Clinical Research 17

Features of Small Pharma Less formalized process Smaller teams More efficient Jack- of- all- trades Research by phone Smart screening instead of high throughput screening One- trick pony 18

Skills Required in Pharma - Research - Team dynamics management Communica<on Relevant to audience Concise ü How to educate your supervisor & peer? General knowledge in drug discovery process General knowledge and apprecia<on of other disciplines Medicinal Chemistry Analy<cal Chemistry Pharmacokine<cs Pharmaceu<cs 19

Skills Required in Pharma - Beyond Research - Project Manager Licensing/Business Development Science Intelligence Regulatory Affairs Clinical Research Technical Writer Technical Trainer 20

Thank You Iok- Hou Pang, PhD 817-735- 2960 iok- hou.pang@unthsc.edu